Абстрактный

Pharmacogenomic testing to guide treatment using antipsychotic medications

David A Mrazek

This review evaluates the utilization of pharmacogenomic testing to guide treatment with antipsychotic medications as well as the evidence supporting the use of pharmacogenomic testing. There are two basic objectives for using pharmacogenomic testing. The first pharmacogenomic objective is to minimize adverse effects. The second pharmacogenomic objective is to improve clinical outcomes. While available pharmacogenomic testing has been demonstrated to increase the likelihood of achieving a good response, the primary current indication is to improve patient safety.